They produced the following three alternative groups: group 1 (minimally invasive FTC with wild-type TERT and mutant type TERT; encapsulated angioinvasive FTC with wild-type TERT), group 2 (widely invasive FTC with wild-type TERT), and group 3 (encapsulated angioinvasive FTC with mutant TERT; widely invasive FTC with mutant type TERT). This evidence concerns the gene TERT and thyroid cancer, nonmedullary, 2.